Hpv vaccine manufacture

Patent metadata

Field	Value
Publication number	US-2024131140-A1
Application number	US-202218276578-A
Country	US
Kind code	A1
Filing date	Feb 9, 2022
Priority date	Feb 11, 2021
Publication date	Apr 25, 2024
Grant date	—

Abstract

Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.

First claim

1 . A method for the preparation of a human papillomavirus (HPV) vaccine composition comprising the following steps:
(i) adsorption of one or more HPV antigen(s) on a metallic salt, and (ii) addition of a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in

2 . The method according to claim 1 , wherein the one or more HPV antigen(s) are selected from the group consisting of HPV late proteins L1, L2, chimeric L1 and chimeric L1/L2 proteins.

3 . The method according to claim 2 , wherein the one or more HPV antigen(s) are selected from HPV L1 VLPs (virus like particles).

4 . The method according to claim 3 , wherein the HPV L1 VLPs are produced in E. coli, yeast cells or in a baculovirus expression system.

5 . The method according to claim 4 , wherein the HPV L1 VLPs are produced in E. coli.

6 . The method according to claim 1 , wherein each of the one or more HPV antigen(s) are from a HPV type selected from HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 67, 68, 70, 73 and 82, more preferably from HPV types 6, 11, 16, 18, 31, 33, 115, 52 and 58.

7 . The method according to claim 1 , wherein the one or more HPV antigen(s) comprise HPV antigen(s) from HPV types 16 and 18.

8 . The method according to claim 1 , wherein the one or more HPV antigen(s) comprise HPV antigen(s) from HPV types 6, 11, 16, and 18.

9 . The method according to claim 1 , wherein the one or more HPV antigen(s) comprise HPV antigen(s) from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

10 . The method according to claim 9 , wherein the one or more HPV antigen(s) further comprise HPV antigen(s) from HPV types 35, 39 and/or 59.

11 . The method according to claim 1 , wherein the one or more HPV antigen(s) comprise L1 VLPs from HPV types 16 and 18.

12 . The method according to claim 1 , wherein the one or more HPV antigen(s) comprise L1 VLPs from HPV types 6, 11, 16, and 18.

13 . The method according to claim 1 , wherein the one or more HPV antigen(s) comprise or consist of L1 VLPs from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

14 . The method according to claim 13 , wherein the one or more HPV antigen(s) further comprise L1 VLPs from HPV types 35, 39 and/or 59 L1 VLPs.

15 . The method according to claim 1 , wherein the metallic salt comprises aluminum.

16 . The method according to claim 15 , wherein the metallic salt is selected from the group consisting of AlOOH, AlPO 4 , AlHO 9 PS −3 and AlHO 5 P.

17 . The method according to claim 1 , wherein the glycolipid based TLR4 agonist is selected from MPL, GLA, SLA, OM-174, CCL-34, RC-529, PET-Lipid A, ONO-4007 and dLOS.

18 . The method according to claim 1 further comprising the step of adding a metallic salt to the HPV vaccine composition.

19 . The method of claim 1 , wherein
the one or more HPV antigen(s) comprise L1 VLPs from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, the metallic salt comprises aluminum, and the glycolipid based TLR4 agonist is MPL.

20 . A HPV vaccine composition obtained by the method of claim 1 .

21 . The HPV vaccine composition of claim 20 wherein the metallic ion which is part of the metallic salt is Al + and the amount of Al + in the HPV vaccine composition is from 100 to 500 μg/dose.

22 . The HPV vaccine composition of claim 20 wherein the glycolipid based TLR4 ligand is MPL and the amount of MPL in the HPV vaccine composition is from 10 to 50 μg/dose.

23 . The HPV vaccine composition of claim 20 , wherein the ratio of glycolipid based TLR4 ligand:metallic salt in the HPV vaccine composition is from 1:2 to 1:20.

24 . (canceled)

25 . The HPV vaccine of claim 20 for preventing or treating a HPV infection or associated disease in a subject.

26 . A method of preventing or treating an infection or disease caused by HPV comprising the administration of an effective amount of the HPV vaccine of to claim 20 to a patient in need thereof.

27 . The method according to claim 1 , wherein the one or more HPV antigen(s) consist of L1 VLPs from HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

Assignees

• Glaxosmithkline Biologicals Sa
• Xiamen Innovax Biotech Co Ltd

Inventors

• Bayat Babak
• Henderickx Véronique
• Vuylsteke Bram

Classifications

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• C12N2710/20034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title

• A61P31/20

  for DNA viruses · CPC title